What question did this study set out to answer?

To evaluate the expanding therapeutic indications of amiodarone, its comparative safety relative to other antiarrhythmics, and surveillance protocols for chronic administration.

July 1, 1997Clinical CardiologyOpen Access

Amiodarone: The expanding antiarrhythmic role and how to follow a patient on chronic therapy

View Full Paper

Ask AI

Bookmark

To evaluate the expanding therapeutic indications of amiodarone, its comparative safety relative to other antiarrhythmics, and surveillance protocols for chronic administration.
Reviewed clinical trial evidence on oral and intravenous amiodarone across ventricular and supraventricular arrhythmias.
Assessed dose-minimization strategies, laboratory monitoring regimens, and efficacy markers during long-term maintenance.
Amiodarone exhibits low to negligible proarrhythmic potential and does not increase mortality in structural heart disease, in contrast to class I antiarrhythmic agents.
The compound does not aggravate congestive heart failure and may improve left ventricular ejection fraction and exercise capacity.
Lower dosing regimens significantly reduce the incidence of serious adverse effects, supporting its expanded use with routine clinical surveillance.

Structured PICO

Population

Patients with arrhythmias, including refractory ventricular arrhythmias, survivors of myocardial infarction, and congestive heart failure

Intervention

Amiodarone (oral and intravenous)

Comparator

Class I antiarrhythmic agents or conventional therapy

Amiodarone is an effective and safe antiarrhythmic option, particularly in patients with structural heart disease or compromised ventricular function, provided it is used at the lowest effective dose with regular monitoring.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Supports amiodarone use with monitoring in structural heart disease; extends evidence but leaves open need for contemporary randomized confirmation.

Cite This Study

Bramah N. Singh (1997) studied this question.

synapsesocial.com/papers/6a73250c7c93a8454ca0bb27 https://doi.org/10.1002/clc.4960200706

Topics

Persistent AF management Atrial fibrillation HFrEF treatment Heart failure

View Full Paper

Ask AI

Bookmark

Implication

Supports amiodarone use with monitoring in structural heart disease; extends evidence but leaves open need for contemporary randomized confirmation.

Amiodarone: The expanding antiarrhythmic role and how to follow a patient on chronic therapy

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Topics

Amiodarone: The expanding antiarrhythmic role and how to follow a patient on chronic therapy

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider